The price-to-earnings ratio for Verve Therapeutics Inc (NASDAQ: VERV) is above average at N/Ax. The 36-month beta value for VERV is also noteworthy at 2.24. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for VERV is N/A, which is -$5389987.14 below than the current price. The public float for VERV is 65.76M, and at present, short sellers hold a 27.37% of that float. The average trading volume of VERV on July 01, 2025 was 5.39M shares.
VERV) stock’s latest price update
The stock price of Verve Therapeutics Inc (NASDAQ: VERV) has dropped by -0.27 compared to previous close of 11.23. Despite this, the company has seen a gain of 0.27% in its stock price over the last five trading days. fool.com reported 2025-06-20 that Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program, VERVE-102.
VERV’s Market Performance
VERV’s stock has risen by 0.27% in the past week, with a monthly rise of 151.69% and a quarterly rise of 145.08%. The volatility ratio for the week is 0.96% while the volatility levels for the last 30 days are 6.29% for Verve Therapeutics Inc The simple moving average for the last 20 days is 30.45% for VERV’s stock, with a simple moving average of 87.44% for the last 200 days.
Analysts’ Opinion of VERV
Many brokerage firms have already submitted their reports for VERV stocks, with Cantor Fitzgerald repeating the rating for VERV by listing it as a “Overweight.” The predicted price for VERV in the upcoming period, according to Cantor Fitzgerald is N/A based on the research report published on April 15, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VERV reach a price target of $15. The rating they have provided for VERV stocks is “Buy” according to the report published on April 08th, 2024.
Canaccord Genuity gave a rating of “Buy” to VERV, setting the target price at $29 in the report published on April 13th of the previous year.
VERV Trading at 77.86% from the 50-Day Moving Average
After a stumble in the market that brought VERV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.80% of loss for the given period.
Volatility was left at 6.29%, however, over the last 30 days, the volatility rate increased by 0.96%, as shares surge +133.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +143.46% upper at present.
During the last 5 trading sessions, VERV rose by +0.04%, which changed the moving average for the period of 200-days by +90.37% in comparison to the 20-day moving average, which settled at $8.58. In addition, Verve Therapeutics Inc saw 135.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERV starting from Kathiresan Sekar, who sale 9,822 shares at the price of $4.15 back on Apr 02 ’25. After this action, Kathiresan Sekar now owns 346,686 shares of Verve Therapeutics Inc, valued at $40,761 using the latest closing price.
Nickerson Joan, the Chief Administrative Officer of Verve Therapeutics Inc, sale 2,777 shares at $4.15 during a trade that took place back on Apr 02 ’25, which means that Nickerson Joan is holding 17,420 shares at $11,525 based on the most recent closing price.
Stock Fundamentals for VERV
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.36 for the gross margin
The net margin for Verve Therapeutics Inc stands at -3.04. The total capital return value is set at -0.37. Equity return is now at value -34.26, with -26.89 for asset returns.
Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is N/A.
Currently, EBITDA for the company is -221.91 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 16.31. The receivables turnover for the company is N/Afor trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.84.
Conclusion
In summary, Verve Therapeutics Inc (VERV) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
